Tizanidine Tablet
Product Images NDC 70518-1598

9 FDA label images from Remedyrepack Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Tizanidine (NDC 70518-1598). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Mm1 (Tizanidine 4mg 70518 1598 00)

Mm1 (Tizanidine 4mg 70518 1598 00)
Tizanidine 4 mg tablet label showing 30 count package. The label includes the proprietary name, strength, dosage form, and quantity. It displays the NDC number 70518-1598-00, manufacturer information (Unichem Pharma Inc., Hasbrouck Heights, NJ), and repackager information (RemedyRepack Inc., Indiana, PA). Additional directions include storage instructions and a reference to the package insert for use.*
FDA Label Image

Mm2 (Tizanidine 4mg 70518 1598 01)

Mm2 (Tizanidine 4mg 70518 1598 01)
Tizanidine 4 mg oral tablets packaging label showing quantity of 60 tablets. Label includes drug name, strength, dosage form, and repackager information RemedyRepack Inc. The label notes storage temperature instructions and includes a QR code and caution to keep out of reach of children.*
FDA Label Image

Mm3 (Tizanidine 4mg 70518 1598 02)

Mm3 (Tizanidine 4mg 70518 1598 02)
Tizanidine 4 mg tablets packaging label showing a quantity of 15 tablets. The label includes the NDC number 70518-1598-02, manufacturer Unichem Pharma Inc., and repackager RemedyRepack Inc. It indicates storage instructions and advises to see the package insert for directions for use.*
FDA Label Image

Mm4 (Tizanidine 4mg 70518 1598 03)

Mm4 (Tizanidine 4mg 70518 1598 03)
Label for Tizanidine 4 mg oral tablets, packaged in a quantity of 30. The label indicates the product is repackaged by RemedyRepack Inc. It includes storage instructions, manufacturer information (Unichem Pharma Inc.), and a QR code. The label states 'RX ONLY' and directs users to see the package insert for directions.*
FDA Label Image

Mm5 (Tizanidine 4mg 70518 1598 04)

Mm5 (Tizanidine 4mg 70518 1598 04)
Tizanidine 4 mg tablet label showing medication quantity of 90 tablets. The label includes the proprietary name Tizanidine, strength 4 mg, and dosage form as tablet. It is repackaged by RemedyRepack Inc. with directions to see the package insert for use. Manufacturer information and storage instructions are also stated, along with a QR code.*
FDA Label Image

Molecular Structure (Ee6ccf71 79ba 43ca 9a1a 1cab1d5a0c6c 01)

Molecular Structure (Ee6ccf71 79ba 43ca 9a1a 1cab1d5a0c6c 01)
Chemical structure of Tizanidine hydrochloride, showing a chloro-substituted aromatic ring and attached heterocyclic groups including nitrogen and sulfur atoms, associated with HCl.*
FDA Label Image

Figure-1 (Ee6ccf71 79ba 43ca 9a1a 1cab1d5a0c6c 02)

Figure-1 (Ee6ccf71 79ba 43ca 9a1a 1cab1d5a0c6c 02)
A line graph showing plasma Tizanidine concentration (ng/mL) over time (hours) from dosing, comparing four conditions: 2 x 4 mg tablets with food, 2 x 4 mg tablets without food, 2 x 4 mg capsules with food, and 2 x 4 mg capsules without food. Concentrations peak early and decline over 24 hours.*
FDA Label Image

Figure 3 (Ee6ccf71 79ba 43ca 9a1a 1cab1d5a0c6c 03)

Figure 3 (Ee6ccf71 79ba 43ca 9a1a 1cab1d5a0c6c 03)
A line graph showing improvement in Ashworth Score over six hours post-dose comparing 16 mg tizanidine, 8 mg tizanidine, and placebo. The y-axis represents improvement scores; the x-axis represents hours after dosing. Data points include error bars for variability.*
FDA Label Image

Figure 4 (Ee6ccf71 79ba 43ca 9a1a 1cab1d5a0c6c 04)

Figure 4 (Ee6ccf71 79ba 43ca 9a1a 1cab1d5a0c6c 04)
A line graph comparing improvement in Ashworth Score between tizanidine (mean dose 28.8 mg) and placebo groups at three study points: End of Titration (Study Week 3), End of Maintenance (Study Week 7), and Endpoint (Last Observation Carried Forward). The y-axis represents improvement in score from -6 to 2, with data points plotted for each group showing mean values and error bars.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.